ARTICLE | Company News
MABLife, ElsaLys Biotech deal
August 17, 2015 7:00 AM UTC
MABLife granted ElsaLys exclusive worldwide rights to develop and commercialize MAT-302. ElsaLys said it will develop two versions of the antibody, one to treat macular degeneration and one to treat ...